"Bortezomib" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.
| Descriptor ID |
D000069286
|
| MeSH Number(s) |
D01.029.260.110.500 D01.132.285.500 D02.203.200.500 D03.383.679.450
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bortezomib".
Below are MeSH descriptors whose meaning is more specific than "Bortezomib".
This graph shows the total number of publications written about "Bortezomib" by people in this website by year, and whether "Bortezomib" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bortezomib" by people in Profiles.
-
Identification of ClpP Dual Isoform Disruption as an Antisporulation Strategy for Clostridioides difficile. J Bacteriol. 2022 02 15; 204(2):e0041121.
-
Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma. 2022 03; 63(3):710-721.
-
Pluronic block copolymers enhance the anti-myeloma activity of proteasome inhibitors. J Control Release. 2019 07 28; 306:149-164.
-
Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner. PLoS One. 2017; 12(11):e0186924.
-
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):236-242.
-
Bortezomib Based Chemotherapy for Light Chain Deposition Disease. J Assoc Physicians India. 2016 08; 64(8):97-98.
-
G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation. Carcinogenesis. 2010 Jul; 31(7):1230-7.
-
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res. 2010 Jan 01; 70(1):150-9.
-
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Nov; 115(2):215-20.
-
MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res. 2009 Feb 01; 15(3):933-42.